EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy

Mette Julsgaard, Jantien W Wieringa, Simon M D Baunwall, Bo M Bibby, Gertjan J A Driessen, Linda Kievit, Jacob B Brodersen, Anja Poulsen, Jens Kjeldsen, Mette M Hansen, Hai Q Tang, Christina L Balmer und 14 weitere

Clinical Gastroenterology and Hepatology · 2025

DOI: 10.1016/j.cgh.2024.01.008 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Mette Julsgaard und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; Center for Molecular Prediction of Inflammatory Bowel Dis…. Hauptthemen laut MEDLINE: Ustekinumab. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aarhus University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Evidence on ustekinumab safety in pregnancy is gradually expanding, but its clearance in the postnatal period is unknown. The aim of this study was to investigate ustekinumab concentrations in umbilical cord blood and rates of clearance after birth, as well as how these correlate with maternal drug concentrations, risk of infection, and developmental milestones during the first year of life. METHODS: Pregnant women with inflammatory bowel disease were prospectively recruited from 19 hospitals in Denmark and the Netherlands between 2018 and 2022. Infant infections leading to hospitalization/antibiotics and developmental milestones were assessed. Serum ustekinumab concentrations were measured at delivery and specific time points. Nonlinear regression analysis was applied to estimate clearance. RESULTS: In 78 live-born infants from 76 pregnancies, we observed a low risk of adverse pregnancy outcomes and normal developmental milestones. At birth, the median infant-mother ustekinumab ratio was 2.18 (95% confidence interval, 1.69-2.81). Mean time to infant clearance was 6.7 months (95% confidence interval, 6.1-7.3 months). One in 4 infants at 6 months had an extremely low median concentration of 0.015 μg/mL (range 0.005-0.12 μg/mL). No variation in median ustekinumab concentration was noted between infants with (2.8 [range 0.4-6.9] μg/mL) and without (3.1 [range 0.7-11.0] μg/mL) infections during the first year of life (P = .41). CONCLUSIONS: No adverse signals after intrauterine exposure to ustekinumab were observed with respect to pregnancy outcome, infections, or developmental milestones during the first year of life. Infant ustekinumab concentration was not associated with risk of infections. With the ustekinumab clearance profile, live attenuated vaccination from 6 months of age seems of low risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabHumansFemalePregnancyInfant, NewbornAdultProspective StudiesInfantNetherlandsDenmarkInflammatory Bowel DiseasesFetal BloodMalePregnancy OutcomePregnancy ComplicationsYoung Adult

Stichwörter der Autor:innen

Infant InfectionsInflammatory Bowel DiseasePregnancyUstekinumab

Substanzen

Ustekinumab

Autor:innen und Institutionen

  • Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen,…
  • Department of Pediatrics, Haaglanden Medical Center, The Hague, the Netherlands; Division of Paediatric Infectious Diseases and Immunology, Department of Pediatrics, Sophia Children's Hospital, Erasmus MC University Med…
  • Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Biostatistics, University of Aarhus, Aarhus, Denmark.
  • Department of Pediatrics, MosaKids Children's Hospital, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Department of Medicine, Gjødstrup Hospital, Gjødstrup, Denmark.

Förderung

  • Aarhus University Hospital

Zitieren

APA

Julsgaard, M., Wieringa, J. W., Baunwall, S. M. D., Bibby, B. M., Driessen, G. J. A., Kievit, L., Brodersen, J. B., Poulsen, A., Kjeldsen, J., Hansen, M. M., Tang, H. Q., Balmer, C. L., Glerup, H., Seidelin, J. B., Haderslev, K. V., Svenningsen, L., Wildt, S., Juel, M. A., Neumann, A., …, & NEXUS Collaborator Group (2025). Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.01.008

Vancouver

Julsgaard M, Wieringa JW, Baunwall SMD, Bibby BM, Driessen GJA, Kievit L, et al. Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.01.008

BibTeX
@article{Julsgaard2025,
  author = {Julsgaard, Mette and Wieringa, Jantien W and Baunwall, Simon M D and Bibby, Bo M and Driessen, Gertjan J A and Kievit, Linda and Brodersen, Jacob B and Poulsen, Anja and Kjeldsen, Jens and Hansen, Mette M and Tang, Hai Q and Balmer, Christina L and Glerup, Henning and Seidelin, Jakob B and Haderslev, Kent V and Svenningsen, Lise and Wildt, Signe and Juel, Mie A and Neumann, Anders and Fuglsang, Jens and Jess, Tine and Haase, Anne-Mette and Hvas, Christian L and Kelsen, Jens and Janneke van der Woude, C and NEXUS Collaborator Group, NEXUS Collaborator Group},
  title = {Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1016/j.cgh.2024.01.008}
}
Kostenlos starten →